<p>佛罗里达州奥兰多 / ACCESS Newswire /2025 年 12 月 26 日/ RedChip Companies 将在本周六（12 月 27 日）东部时间晚上 7 点在 Bloomberg TV 播出与 Processa Pharmaceuticals, Inc. 和 60 Degrees Pharmaceuticals, Inc. 的访谈，节目名为 RedChip <em>Small Stocks, Big Money™</em>，这是一个赞助节目。Bloomberg TV 在美国大约有 7300 万家庭可收看。</p>
<p><strong>完整访谈请访问：</strong></p>
<ul>
<li>PCSA: https://www.redchip.com/assets/access/pcsa_access</li>
<li>SXTP: https://www.redchip.com/assets/access/sxtp_access</li>
</ul>
<p>Processa Pharmaceuticals 的创始人兼总裁、研发负责人 David Young 博士在 Bloomberg TV 的 RedChip Small Stocks Big Money™ 节目中讨论公司的下一代癌症（NGC）平台，并提供其正在进行的 NGC-Cap 二期研究的临床更新，该研究涉及 PCS6422 和卡培他滨的组合，针对晚期或转移性乳腺癌患者。Young 博士强调了初步的二期数据，表明 NGC-Cap 显著增加了对卡培他滨抗癌代谢物的暴露，同时保持了与标准卡培他滨治疗相当的安全性。他还讨论了该项目的差异化药理特征，包括减少与剂量限制性副作用相关的有毒代谢物的暴露，并概述了公司计划在 2026 年初进行的中期分析。</p>
<p>60 Degrees Pharmaceuticals 的首席执行官 Geoffrey Dow 博士在 Bloomberg TV 的 RedChip Small Stocks Big Money™ 节目中讨论公司的使命，即通过创新的小分子治疗药物来对抗传染病。Dow 博士将重点介绍 ARAKODA®（塔非喹），这是一种与美国陆军共同开发的 FDA 批准抗疟药，以及其在美国不断扩展的商业足迹。他还将概述公司计划将塔非喹的 FDA 批准扩展到巴贝斯虫病——一种日益增长的蜱媒疾病，管理层认为其发生率远低于 CDC 的估计，并且目前没有 FDA 批准的治疗药物。60 Degrees Pharmaceuticals 正在进行两项临床试验（住院巴贝斯虫病患者和复发患者），并计划在近期启动第三项试验。60 Degrees Pharmaceuticals 已获得塔非喹用于巴贝斯虫病的孤儿药地位，并在疟疾适应症上拥有至 2035 年的专利独占权。</p>
<p>PCSA 和 SXTP 是 RedChip Companies 的客户。请阅读我们的完整披露信息，网址为 https://www.redchip.com/legal/disclosures。</p>
<p><strong>关于 Processa Pharmaceuticals, Inc.</strong></p>
<p>Processa 是一家临床阶段的制药公司，专注于开发具有更好安全性和疗效的下一代癌症（NGC）药物。Processa 的 NGC 药物是现有 FDA 批准的肿瘤治疗药物的改良版，旨在改变这些药物的代谢和/或分布，同时保持现有的杀伤癌细胞机制。通过将其新型肿瘤管线与经过验证的抗癌活性分子及其监管科学方法相结合，Processa 的战略是通过高效的监管路径，为癌症患者开发更有效的治疗选择，改善耐受性。除了核心肿瘤项目外，Processa 还积极寻求非肿瘤资产的战略合作伙伴关系，以释放额外价值。</p>
<p>欲了解更多信息，请访问我们的网站 www.processapharma.com。</p>
<p><strong>关于 60 Degrees Pharmaceuticals, Inc.</strong></p>
<p>60 Degrees Pharmaceuticals, Inc. 成立于 2010 年，专注于开发和商业化用于治疗和预防媒介传播疾病的新药物。该公司于 2018 年获得美国食品药品监督管理局对其主要产品 ARAKODA®（塔非喹）用于疟疾预防的批准。ARAKODA 在美国和澳大利亚均可商业销售。60 Degrees Pharmaceuticals, Inc. 还与美国和澳大利亚的知名研究和学术机构合作。60 Degrees Pharmaceuticals, Inc. 总部位于华盛顿特区，在澳大利亚设有子公司。了解更多信息，请访问 www.60degreespharma.com。</p>
<p><strong>关于 RedChip Companies</strong></p>
<p>RedChip Companies 是一家 Inc. 5000 公司，是一家国际投资者关系、媒体和研究公司，专注于微型和小型公司。RedChip 于 1992 年成立，最初是一家小型研究公司，因对新兴蓝筹公司的覆盖而获得早期认可，如苹果、星巴克、Daktronics、Winnebago 和耐克。在过去的 33 年中，RedChip 已发展成为一家全方位服务的投资者关系和媒体公司，为其客户提供具体、可衡量的结果，客户包括美国钢铁、Perfumania、Cidara Therapeutics 和 Celsius Holdings 等。我们的通讯 <em>Small Stocks, Big Money™</em> 每周在线发送给 60,000 名投资者。RedChip 为微型和小型公司开发了行业内最全面的服务平台。这些服务包括：全球股票研究的分发网络；在美国主要城市的零售和机构路演；向股票经纪人、RIA、机构和家族办公室的外部营销；生成数百万独特投资者浏览量的数字媒体投资者关系平台；投资者网络研讨会和小组电话；每周在 Bloomberg US 播出的电视节目 <em>Small Stocks, Big Money™</em>；在地方和国家市场的电视广告；公司和产品视频；网站设计；以及传统的投资者关系服务，包括新闻稿撰写、投资者演示文稿开发、季度电话会议脚本撰写、战略咨询、资本筹集等。RedChip 还提供 RedChat™，这是一种专有的 AI 驱动聊天机器人，分析所有纳斯达克和纽约证券交易所上市公司的 SEC 文件和公司披露，为投资者提供即时、按需的洞察。</p>
<p>欲了解更多有关 RedChip 产品和服务的信息，请访问：</p>
<p>https://www.redchip.com/corporate/investor_relations</p>
<p>“发现明日蓝筹股”™</p>
<p>在 LinkedIn 上关注 RedChip: https://www.linkedin.com/company/redchip/</p>
<p>在 Facebook 上关注 RedChip: https://www.facebook.com/RedChipCompanies</p>
<p>在 Instagram 上关注 RedChip: https://www.instagram.com/redchipcompanies/</p>
<p>在 Twitter 上关注 RedChip: https://twitter.com/RedChip</p>
<p>在 YouTube 上关注 RedChip: https://www.youtube.com/@redchip</p>
<p>在 Rumble 上关注 RedChip: https://rumble.com/c/c-3068340</p>
<p>订阅我们的邮件列表: https://www.redchip.com/newsletter/latest</p>
<p><strong>联系方式：</strong></p>
<p>Dave Gentry</p>
<p>RedChip Companies Inc.</p>
<p>1-800-REDCHIP (733-2447)</p>
<p>1-407-644-4256</p>
<p>info@redchip.com</p>
<p><strong>来源：</strong> RedChip Companies, Inc.</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>

PCSA

<p>RedChip 公司将在 12 月 27 日东部时间晚上 7 点于彭博电视台的 “Small Stocks, Big Money” 节目中播出与 Processa Pharmaceuticals 和 60 Degrees Pharmaceuticals 的采访。Processa 将讨论其下一代癌症平台，而 60 Degrees 将重点介绍其抗疟药 ARAKODA® 及其 FDA 扩大批准的计划。这两家公司都是 RedChip 的客户</p>

<p>ORLANDO, FL / ACCESS Newswire / December 26, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc.  and 60 Degrees Pharmaceuticals, Inc.  on the RedChip <em>Small Stocks, Big Money™</em> show, a sponsored program on Bloomberg TV this Saturday, December 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.</p>
<div class="lb-trans"><p>佛罗里达州奥兰多 / ACCESS Newswire /2025 年 12 月 26 日/ RedChip Companies 将在本周六（12 月 27 日）东部时间晚上 7 点在 Bloomberg TV 播出与 Processa Pharmaceuticals, Inc. 和 60 Degrees Pharmaceuticals, Inc. 的访谈，节目名为 RedChip <em>Small Stocks, Big Money™</em>，这是一个赞助节目。Bloomberg TV 在美国大约有 7300 万家庭可收看。</p>
</div><p><strong>Access the interviews in their entirety at:</strong></p>
<div class="lb-trans"><p><strong>完整访谈请访问：</strong></p>
</div><ul>
<li>PCSA: https://www.redchip.com/assets/access/pcsa_access</li>
<li>SXTP: https://www.redchip.com/assets/access/sxtp_access</li>
</ul>
<div class="lb-trans"><ul>
<li>PCSA: https://www.redchip.com/assets/access/pcsa_access</li>
<li>SXTP: https://www.redchip.com/assets/access/sxtp_access</li>
</ul>
</div><p>David Young, PharmD, PhD, Founder and President, Research and Development, of Processa Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's Next Generation Cancer (NGC) platform and provide a clinical update on its ongoing Phase 2 study of NGC-Cap, the combination of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer. Dr. Young highlights preliminary Phase 2 data demonstrating that NGC-Cap significantly increases exposure to capecitabine's cancer-killing metabolites while maintaining a safety profile comparable to standard capecitabine therapy. He also addresses the program's differentiated pharmacologic profile, including reduced exposure to toxic catabolite metabolites associated with dose-limiting side effects, and outlines the Company's planned interim analysis expected in early 2026.</p>
<div class="lb-trans"><p>Processa Pharmaceuticals 的创始人兼总裁、研发负责人 David Young 博士在 Bloomberg TV 的 RedChip Small Stocks Big Money™ 节目中讨论公司的下一代癌症（NGC）平台，并提供其正在进行的 NGC-Cap 二期研究的临床更新，该研究涉及 PCS6422 和卡培他滨的组合，针对晚期或转移性乳腺癌患者。Young 博士强调了初步的二期数据，表明 NGC-Cap 显著增加了对卡培他滨抗癌代谢物的暴露，同时保持了与标准卡培他滨治疗相当的安全性。他还讨论了该项目的差异化药理特征，包括减少与剂量限制性副作用相关的有毒代谢物的暴露，并概述了公司计划在 2026 年初进行的中期分析。</p>
</div><p>Geoffrey Dow, PhD, CEO of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's mission to combat infectious diseases with innovative, small-molecule therapeutics. Dr. Dow will highlight the potential of ARAKODA® (tafenoquine), an FDA-approved antimalarial developed with the U.S. Army, and its expanding commercial footprint in the U.S. He will also outline the company's plan to expand FDA approval for tafenoquine to babesiosis-a growing tick-borne illness, incidence of which management believes is vastly underrepresented by CDC estimates and for which there is no FDA-approved therapy. 60 Degrees Pharmaceuticals has two clinical trials (hospitalized babesiosis patients and relapsing patients) underway, and initiation of a third planned near-term. 60 Degrees Pharmaceuticals has Orphan Drug status for tafenoquine for babesiosis and patent exclusivity for the malaria indication through 2035.</p>
<div class="lb-trans"><p>60 Degrees Pharmaceuticals 的首席执行官 Geoffrey Dow 博士在 Bloomberg TV 的 RedChip Small Stocks Big Money™ 节目中讨论公司的使命，即通过创新的小分子治疗药物来对抗传染病。Dow 博士将重点介绍 ARAKODA®（塔非喹），这是一种与美国陆军共同开发的 FDA 批准抗疟药，以及其在美国不断扩展的商业足迹。他还将概述公司计划将塔非喹的 FDA 批准扩展到巴贝斯虫病——一种日益增长的蜱媒疾病，管理层认为其发生率远低于 CDC 的估计，并且目前没有 FDA 批准的治疗药物。60 Degrees Pharmaceuticals 正在进行两项临床试验（住院巴贝斯虫病患者和复发患者），并计划在近期启动第三项试验。60 Degrees Pharmaceuticals 已获得塔非喹用于巴贝斯虫病的孤儿药地位，并在疟疾适应症上拥有至 2035 年的专利独占权。</p>
</div><p>PCSA and SXTP are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.</p>
<div class="lb-trans"><p>PCSA 和 SXTP 是 RedChip Companies 的客户。请阅读我们的完整披露信息，网址为 https://www.redchip.com/legal/disclosures。</p>
</div><p><strong>About Processa Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Processa Pharmaceuticals, Inc.</strong></p>
</div><p>Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa's NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa's strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path. In addition to its core oncology programs, Processa is actively pursuing strategic partnerships for non-oncology assets to unlock additional value.</p>
<div class="lb-trans"><p>Processa 是一家临床阶段的制药公司，专注于开发具有更好安全性和疗效的下一代癌症（NGC）药物。Processa 的 NGC 药物是现有 FDA 批准的肿瘤治疗药物的改良版，旨在改变这些药物的代谢和/或分布，同时保持现有的杀伤癌细胞机制。通过将其新型肿瘤管线与经过验证的抗癌活性分子及其监管科学方法相结合，Processa 的战略是通过高效的监管路径，为癌症患者开发更有效的治疗选择，改善耐受性。除了核心肿瘤项目外，Processa 还积极寻求非肿瘤资产的战略合作伙伴关系，以释放额外价值。</p>
</div><p>For more information, visit our website at www.processapharma.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问我们的网站 www.processapharma.com。</p>
</div><p><strong>About 60 Degrees Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 60 Degrees Pharmaceuticals, Inc.</strong></p>
</div><p>60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.</p>
<div class="lb-trans"><p>60 Degrees Pharmaceuticals, Inc. 成立于 2010 年，专注于开发和商业化用于治疗和预防媒介传播疾病的新药物。该公司于 2018 年获得美国食品药品监督管理局对其主要产品 ARAKODA®（塔非喹）用于疟疾预防的批准。ARAKODA 在美国和澳大利亚均可商业销售。60 Degrees Pharmaceuticals, Inc. 还与美国和澳大利亚的知名研究和学术机构合作。60 Degrees Pharmaceuticals, Inc. 总部位于华盛顿特区，在澳大利亚设有子公司。了解更多信息，请访问 www.60degreespharma.com。</p>
</div><p><strong>About RedChip Companies</strong></p>
<div class="lb-trans"><p><strong>关于 RedChip Companies</strong></p>
</div><p>RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 33 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, Cidara Therapeutics, and Celsius Holdings, among others. Our newsletter, <em>Small Stocks, Big Money™,</em> is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, <em>Small Stocks, Big Money™</em>, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.</p>
<div class="lb-trans"><p>RedChip Companies 是一家 Inc. 5000 公司，是一家国际投资者关系、媒体和研究公司，专注于微型和小型公司。RedChip 于 1992 年成立，最初是一家小型研究公司，因对新兴蓝筹公司的覆盖而获得早期认可，如苹果、星巴克、Daktronics、Winnebago 和耐克。在过去的 33 年中，RedChip 已发展成为一家全方位服务的投资者关系和媒体公司，为其客户提供具体、可衡量的结果，客户包括美国钢铁、Perfumania、Cidara Therapeutics 和 Celsius Holdings 等。我们的通讯 <em>Small Stocks, Big Money™</em> 每周在线发送给 60,000 名投资者。RedChip 为微型和小型公司开发了行业内最全面的服务平台。这些服务包括：全球股票研究的分发网络；在美国主要城市的零售和机构路演；向股票经纪人、RIA、机构和家族办公室的外部营销；生成数百万独特投资者浏览量的数字媒体投资者关系平台；投资者网络研讨会和小组电话；每周在 Bloomberg US 播出的电视节目 <em>Small Stocks, Big Money™</em>；在地方和国家市场的电视广告；公司和产品视频；网站设计；以及传统的投资者关系服务，包括新闻稿撰写、投资者演示文稿开发、季度电话会议脚本撰写、战略咨询、资本筹集等。RedChip 还提供 RedChat™，这是一种专有的 AI 驱动聊天机器人，分析所有纳斯达克和纽约证券交易所上市公司的 SEC 文件和公司披露，为投资者提供即时、按需的洞察。</p>
</div><p>To learn more about RedChip's products and services, please visit:</p>
<div class="lb-trans"><p>欲了解更多有关 RedChip 产品和服务的信息，请访问：</p>
</div><p>https://www.redchip.com/corporate/investor_relations</p>
<div class="lb-trans"><p>https://www.redchip.com/corporate/investor_relations</p>
</div><p>&#34;Discovering Tomorrow's Blue Chips Today&#34;™</p>
<div class="lb-trans"><p>“发现明日蓝筹股”™</p>
</div><p>Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/</p>
<div class="lb-trans"><p>在 LinkedIn 上关注 RedChip: https://www.linkedin.com/company/redchip/</p>
</div><p>Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies</p>
<div class="lb-trans"><p>在 Facebook 上关注 RedChip: https://www.facebook.com/RedChipCompanies</p>
</div><p>Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/</p>
<div class="lb-trans"><p>在 Instagram 上关注 RedChip: https://www.instagram.com/redchipcompanies/</p>
</div><p>Follow RedChip on Twitter: https://twitter.com/RedChip</p>
<div class="lb-trans"><p>在 Twitter 上关注 RedChip: https://twitter.com/RedChip</p>
</div><p>Follow RedChip on YouTube: https://www.youtube.com/@redchip</p>
<div class="lb-trans"><p>在 YouTube 上关注 RedChip: https://www.youtube.com/@redchip</p>
</div><p>Follow RedChip on Rumble: https://rumble.com/c/c-3068340</p>
<div class="lb-trans"><p>在 Rumble 上关注 RedChip: https://rumble.com/c/c-3068340</p>
</div><p>Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest</p>
<div class="lb-trans"><p>订阅我们的邮件列表: https://www.redchip.com/newsletter/latest</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Dave Gentry</p>
<div class="lb-trans"><p>Dave Gentry</p>
</div><p>RedChip Companies Inc.</p>
<div class="lb-trans"><p>RedChip Companies Inc.</p>
</div><p>1-800-REDCHIP (733-2447)</p>
<div class="lb-trans"><p>1-800-REDCHIP (733-2447)</p>
</div><p>1-407-644-4256</p>
<div class="lb-trans"><p>1-407-644-4256</p>
</div><p>info@redchip.com</p>
<div class="lb-trans"><p>info@redchip.com</p>
</div><p><strong>SOURCE:</strong> RedChip Companies, Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> RedChip Companies, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div>

Processa Pharmaceuticals 和 60 Degrees Pharmaceuticals 的采访将在 Bloomberg 电视台的 RedChip Small Stocks, Big Money(TM) 节目中播出